Management of Breast Cancer After Hodgkin’s Disease

2000 ◽  
Vol 18 (4) ◽  
pp. 765-765 ◽  
Author(s):  
Suzanne L. Wolden ◽  
Steven L. Hancock ◽  
Robert W. Carlson ◽  
Don R. Goffinet ◽  
Stefanie S. Jeffrey ◽  
...  

PURPOSE: To evaluate the incidence, detection, pathology, management, and prognosis of breast cancer occurring after Hodgkin’s disease. PATIENTS AND METHODS: Seventy-one cases of breast cancer in 65 survivors of Hodgkin’s disease were analyzed. RESULTS: The median age at diagnosis was 24.6 years for Hodgkin’s disease and 42.6 years for breast cancer. The relative risk for invasive breast cancer after Hodgkin’s disease was 4.7 (95% confidence interval, 3.4 to 6.0) compared with an age-matched cohort. Cancers were detected by self-examination (63%), mammography (30%), and physician exam (7%). The histologic distribution paralleled that reported in the general population (85% ductal histology) as did other features (27% positive axillary lymph nodes, 63% positive estrogen receptors, and 25% family history). Although 87% of tumors were less than 4 cm, 95% were managed with mastectomy because of prior radiation. Two women underwent lumpectomy with breast irradiation. One of these patients developed tissue necrosis in the region of overlap with the prior mantle field. The incidence of bilateral breast cancer was 10%. Adjuvant systemic therapy was well tolerated; doxorubicin was used infrequently. Ten-year disease-specific survival was as follows: in-situ disease, 100%; stage I, 88%; stage II, 55%; stage III, 60%; and stage IV, zero. CONCLUSION: The risk of breast cancer is increased after Hodgkin’s disease. Screening has been successful in detecting early-stage cancers. Pathologic features and prognosis are similar to that reported in the general population. Repeat irradiation of the breast can lead to tissue necrosis, and thus, mastectomy remains the standard of care in most cases.

2009 ◽  
Vol 12 (3) ◽  
Author(s):  
J. Reeder ◽  
S. Puhalla ◽  
V. Vogel

AbstractThe most important predictor of outcome for women with early stage breast cancer is the presence or absence of metastases in the axillary lymph nodes. In the era of sentinel lymph node biopsies and improved pathology techniques, micrometastatic disease can be diagnosed. The question of whether or not to treat these women as if they have nodal disease remains in doubt. In order to further explore this topic, we identified two cases of women with nodal micrometastases at our institution. A literature review of PUBMED and SABCS abstracts was then performed. In this article, we discuss our results and the emerging clinical debate about the management of nodal micrometastases.


2018 ◽  
Vol 104 (6) ◽  
pp. 429-433 ◽  
Author(s):  
Mariacarla Valli ◽  
Simona Cima ◽  
Paola Fanti ◽  
Barbara Muoio ◽  
Alessandra Vanetti ◽  
...  

Objective: To analyze the impact of adjuvant radiotherapy (RT) on ipsilateral breast recurrence (IBR) and overall survival (OS) in patients older than 69 years with early-stage breast cancer. Methods: From January 2007 to June 2015, we analyzed retrospectively 137 women with estrogen receptor–positive T1–2 invasive breast cancer, with negative axillary lymph nodes, dividing them into 2 subgroups: 70 to 79 years and older than 79 years. Results: After a median follow-up of 43.2 months, the 3-year IBR-free survival in patients treated with surgery plus RT was 98.8% and 92.1% in patients treated with surgery alone, with a significant difference ( p = .01). Radiotherapy did not impact overall survival ( p = .10). A higher percentage of patients aged between 70 and 79 years received RT after conservative surgery if compared with the older subgroup ( p < .01). Conclusions: In elderly women, adjuvant RT reduced the IBR, but did not improve OS.


2007 ◽  
Vol 13 (14) ◽  
pp. 4105-4110 ◽  
Author(s):  
Taku Nakagawa ◽  
Steve R. Martinez ◽  
Yasufumi Goto ◽  
Kazuo Koyanagi ◽  
Minoru Kitago ◽  
...  

2017 ◽  
Vol 13 (5) ◽  
pp. 3299-3302 ◽  
Author(s):  
Lívio Portela Cardoso-Coelho ◽  
Rafael Soares Borges ◽  
Airlane Pereira Alencar ◽  
Larysse Maira Cardoso-Campos-Verdes ◽  
João Paulo da Silva-Sampaio ◽  
...  

1972 ◽  
Vol 58 (6) ◽  
pp. 351-360 ◽  
Author(s):  
Bruno Salvadori ◽  
Rita Zanolla ◽  
Giuseppe Maria De Palo ◽  
Emanuele Galante

Bilateral breast cancer accounts for 3.1% of 3272 cases of malignant breast tumors observed during the period 1956–1965. Of the 104 cases of bilateral cancer selected 12 were synchronous and 92 asynchronous. The treatment was radical mastectomy, followed by radiotherapy in cases with metastatic involvement of the axillary lymph-nodes: in 6 cases not amenable to radical surgery the treatment was tumorectomy plus radiotherapy. As to the 12 patients with synchronous bilateral cancer 6 were alive and free of disease 5 years after the treatment: only 1 case was alive after 10 years. The median survival figure was 7.3 years. For the 92 patients treated for successive bilateral cancer the 5- and 10-year survival rate was 78.5% and 64.5% when calculated from the observation of the first tumor: the correspondent figures calculated from the observation of the second tumor were 48.5% and 33% respectively. The median survival figure was 12.7 and 4.8 years respectively. Survival rates for successive bilateral cancer must be calculated from the observation of the second tumor in order to avoid misleading evaluations: the authors do not consider that bilateral cancer has a prognosis similar or even better than unilateral breast cancer. As to treatment, although there are no unequivocal criteria for regarding bilateral cancer as independent tumors, bilateral radical mastectomy is justified and is the treatment of choice.


Author(s):  
L. Constine ◽  
N. Tarbell ◽  
M. Hudson ◽  
C. Schwartz ◽  
A. Sandhu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document